西沙必利联合血液灌流对CRF维持性血液透析患者胃肠道症状及胃肠激素水平的影响

doi:10.3969/j.issn.1671-7171.2024.05.025

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1179 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To explore the effects of cisapride assisted blood perfusion therapy on gastrointestinal symptoms and gastrointestinal hormone levels in maintenance hemodialysis patients with chronic renal failure (CRF).【Methods】A retrospective analysis was conducted on the clinical data of 72 patients with CRF admitted to our hospital from February 2021 to January 2023. According to the treatment method, they were divided into an observation group and a control group, with 36 cases in each group. Both groups received maintenance hemodialysis treatment, the control group received hemoperfusion treatment, and the observation group received cisapride treatment on the basis of the control group. After 2 weeks of treatment, renal function (Scr), urea nitrogen (BUN), glomerular filtration rate (GFR), gastrointestinal symptoms, gastrointestinal hormones [somatostatin (SS), motilin (MOT), vasoactive intestinal peptide (VIP)], serum fibroblast growth factor 23 (FGF-23), calcitonin gene related peptide (CGRP), tumor necrosis factor alpha (TNF-α) levels, and incidence of adverse reactions were compared between the two groups.【Results】After treatment, Scr and BUN of two groups decreased compared to before treatment, EGER increased compared to that before treatment (P<0.05); There was no statistically significant difference between Scr,BUN and eGER in the two sets (P>0.05). After treatment, the scores of acid reflux, nausea and vomiting, bloating, belching, and constipation in both groups were lower than those before treatment, and the observation group was lower than the control group (P<0.05).After treatment, The level of serum MOT and SS in the observation group was lower than that before treatment and that in the control group, VIP was higher than that before treatment and that in the control group (P<0.05). After treatment, The levels of serum FGF-23 CGRP and TNF-α in two groups were lower than those before treatment, and the observation group was lower than the control group (P<0.05).The incidence of adverse reactions in the observation group was lower than that in the control group, and the difference was statistically significant (P<0.05).【Conclusion】Cisapride assisted hemoperfusion therapy for CRF maintenance hemodialysis can regulate gastrointestinal hormone levels, improve gastrointestinal symptoms, alleviate inflammatory damage, and has high safety.

Key words： Kidney Failure, Chronic Cisapride/TU Renal Dialysis Hemoperfusion Gastrointestinal Hormones/BL

Received: 28 August 2023

PACS:

R692.5

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Dongnan
	YANG Jing
	JIA Zhuanzhao

Cite this article:

WANG Dongnan,YANG Jing,JIA Zhuanzhao. The Effect of Cisapride Combined with Hemoperfusion on Gastrointestinal Symptoms and Gastrointestinal Hormone Levels in CRF Maintenance Hemodialysis Patients[J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(5): 732-735.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2024.05.025 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2024/V41/I5/732

[1] 卿山林,尧鹏,田中,等.血液灌流联合血液透析对慢性肾衰竭患者肾功能、血清炎症因子及CTGF、BMP-7水平的影响[J].川北医学院学报,2021,36(2):201-204.
[2] 杨淑彬,李婷,李晓妮,等.不同中药结肠透析模式对慢性肾脏病患者胃肠道症状和营养状态的影响[J].陕西中医,2022,43(12):1698-1701.
[3] 彭丽艳,高珊,尹树旺,等.瓜蒌宽肠胶囊联合西沙必利对妇科腹部术后胃肠功能的影响[J].解放军医药杂志,2022,34(5):134-136.
[4] 李琳,崔珺,崔艳,等.hs-CRP、NLR及FGF23对慢性肾衰竭维持性血液透析患者的预后评估价值[J].西部医学,2021,33(11):1633-1636.
[5] 白雪梅,李向东,李毅,等.西沙必利治疗慢性肾衰竭患者的临床研究[J].中国临床药理学杂志,2020,36(14):1968-1971.
[6] 中国中西医结合学会肾脏疾病专业委员会.慢性肾衰竭中西医结合诊疗指南[J].中国中西医结合杂志,2015,38(9):313-317.
[7] KARAHAN D, ŞAHIN I. Comparison of gastrointestinal symptoms and findings in renal replacement therapy modalities[J].BMC Nephrol, 2022,23(1):261.
[8] BABOVIC B, DJURANOVIC S, MIHALJEVIC O, et al. Dyspepsia in Montenegrin chronic kidney disease patients undergoing hemodialysis: endoscopic and histopathological features[J].Int Urol Nephrol,2022,54(8):1891-1897.
[9] 王冰月,姜埃利,李春红,等.西沙必利对慢性肾衰竭患者消化道症状及胃肠激素的影响[J].中华肾脏病杂志,2018,34(8):574-578.
[10] 王冰月,姜埃利,李春红,等.西沙必利对老年腹膜透析患者消化道症状及胃肠激素影响的研究[J].中华老年医学杂志,2020,39(2):172-175.
[11] 史耀勋.肾衰宁胶囊治疗慢性肾衰竭非透析颈动脉钙化患者TNF-α及IL-6的影响[J].中国中西医结合肾病杂志,2022,23(1):80-81.
[12] 董佳慧,焦军东.成纤维细胞生长因子-23在慢性肾脏病血管钙化中的作用[J].心血管康复医学杂志,2022,31(4):513-516.
[13] 王舸,李倩.钩藤碱对肾性高血压大鼠血管紧张素、醛固酮及降钙素基因相关肽的影响[J].中西医结合心脑血管病杂志,2022,20(11):1965-1968.
[14] 李子源,刘云,谭荣韶,等.维持性血液透析患者微量元素与微炎症状态的相关性分析[J].中国血液净化,2022,21(7):492.
[15] 高艳玲.HFHD联合西沙必利对慢性CRF患者的炎症因子、肾功能指标及临床疗效分析[J].河北医科大学学报,2022,43(8):909-914.